Medical Doctor Program year 2021 Reported 2019–2021 Source: CMS Open Payments, 2026 publication

James Janousek

Geriatric Medicine Live Oak, FL Medical Doctor

NPI 1972533404 CMS profile 316406

801 Pinewood Sw Dr, Live Oak, FL 32064

Open in the dashboard

General payments

$2,308

154 records reported · program years 2019–2021

Research payments

$0

Paid to them · None reported · program years 2019–2021

Ownership & investment interest

$0

None reported

Through program year 2021, James Janousek of Live Oak, FL is reported in the CMS Open Payments database as having received $2,308 across 154 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Geriatric Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2021 General $129 8
2020 General $1,168 78
2019 General $1,011 68

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Janousek
  • Geriatric Medicine median
  • Middle half of Geriatric Medicine
  • National median

In program year 2025, general payments to James Janousek were reported at $0. Among 512 Geriatric Medicine profiles paid that year, the median was $120 and the middle half received between $37 and $350.

Show as a table
Year James Janousek Geriatric Medicine median Middle half National median
2019 $1,011 $96 $28–$339 $163
2020 $1,168 $99 $28–$262 $114
2021 $129 $94 $27–$318 $132
2022 $0 $103 $34–$338 $149
2023 $0 $109 $39–$320 $160
2024 $0 $125 $36–$371 $164
2025 $0 $120 $37–$350 $169

Breakdown

Who paid General payments · program years 2019–2021
  1. Novo Nordisk Inc $670 46 payments
  2. AstraZeneca Pharmaceuticals LP $367 22 payments
  3. GlaxoSmithKline, LLC. $294 24 payments
  4. Pfizer Inc. $162 10 payments
  5. Merck Sharp & Dohme Corporation $150 8 payments
  6. Sunovion Pharmaceuticals Inc. $114 9 payments
  7. Amarin Pharma Inc. $76 5 payments
  8. Lilly USA, LLC $68 5 payments
  9. Sanofi-Aventis U.S. LLC $64 4 payments
  10. Eisai Inc. $59 4 payments
  11. Other $284 17 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2021
  1. Food and Beverage $2,308 154 payments
Products named General payments · program years 2019–2021
  1. Ozempic $466 33 payments
  2. RYBELSUS $348 25 payments
  3. Tresiba $218 14 payments
  4. SYMBICORT $182 11 payments
  5. Victoza $160 10 payments
  6. TRELEGY ELLIPTA $148 12 payments
  7. JANUVIA $136 7 payments
  8. FARXIGA $134 8 payments
  9. ELIQUIS $130 8 payments
  10. BELSOMRA $120 6 payments
  11. Other $1,648 107 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

154 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Geriatric Medicine in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2021

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record